Cynata Therapeutics Completes Patent Application to Cover Cymerus Stem Cell Technology

Australian stem cell and regenerative medicine company, Cynata Therapeutics Limited (ASX:CYP) announced that it has completed the filing of a patent application with IP Australia that would cover the therapeutic use of its Cymerus™ stem cell technology in the treatment of adverse reactions associated with chimeric antigen receptor T-cell (CAR-T) immunotherapy. This latest patent application follows on from an initial provisional patent application concerning this proposed use of the Cymerus technology, which the Company filed in April 2017.

As quoted in the press release:

Initial preclinical data from studies in mouse models of CAR-T therapy at the University of Massachusetts Amherst demonstrate Cymerus therapeutic mesenchymal stem cells (MSCs) have the potential to ameliorate the effects of CRS and other related adverse reactions, which can be associated with significant risk to patients and in some cases rapid death.

Dr. Kilian Kelly, Cynata’s Vice President, Product Development, said, “CAR-T therapies have demonstrated impressive responses in patients with various types of advanced cancer, in particular blood cancers such as leukaemia and lymphoma.  However, CAR-T therapy can lead to potentially fatal and unpredictable adverse reactions, especially cytokine release syndrome, which may severely limit its uptake.  Initial preclinical data suggest our Cymerus mesenchymal stem cells may play an important role in managing the toxic side effects of CAR-T therapy, which, in turn, could substantially increase its utility and improve patient outcomes. We are thrilled to expand the therapeutic application of Cymerus into this innovative and exciting area of oncology and are continuing to evaluate the benefits of our MSCs in association with CAR-T treatment in ongoing preclinical studies.”

Click here to read the full press release.